Forge Biologics, a Columbus, Ohio-based gene therapy-focused contract development and manufacturing organization, closed a $120m Series B financing.
The round was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace and existing investors Perceptive Xontogeny Venture Fund and Drive Capital. In connection with the financing, Matthew Hammond, Ph.D., of RA Capital, and Fred Callori of the Perceptive Xontogeny Venture Fund will join Forge’s Board of Directors.
The company intends to use the funds to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity, as well as operate its subsidiaries that are advancing novel adeno-associated virus (AAV) gene therapy programs.
Led by Timothy J. Miller, Ph.D., CEO, President and Co-Founder, Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company with a 175,000 square foot facility in Columbus, Ohio which dedicated to AAV viral vector manufacturing, Forge offers end-to-end manufacturing services, including research and toxicology grade AAV production, to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.
Through its subsidiaries, the company is also working to advance a proprietary pipeline of novel gene therapies, including its lead program FBX-101 for the treatment of patients with Krabbe disease, a first-in-human gene therapy utilizing an AAV to deliver a functioning copy of the GALC gene intravenously to cells in the central nervous system (CNS) and peripheral organs.